Key facts
- Zenflow’s last known valuation is $78.5M (Nov 2024).
- It has raised $92.6M across 3 recorded rounds; the latest was Early Stage VC ($19.4M) in Nov 2024.
- Notable investors include Y Combinator, US National Science Foundation, MedTech Innovator, StartX (US), F-Prime Capital — 32 tracked in total.
- Zenflow has filed 5 Form Ds with the SEC since 2017, most recently Nov 2024 ($19.4M sold to 36 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 32 names
- ·Watchlist + deal alerts for Zenflow
Funding rounds
3 roundsAbout Zenflow
Developer of a medical device designed to offer devices for urinary obstruction caused by an enlarged prostate. The company offers treatment that has been designed with the patient experience in mind and relies on a small spring-like coil that gently props open the urethra, restoring its normal function while preserving the natural anatomy, helping patients experience less invasive and less painful treatment.
- Sector
- Healthcare
- HQ
- South San Francisco, CA, United States
- Founded
- 2014
- Employees
- 33
- Website
- zenflow.com/
- Ownership
- Privately Held (backing)
Zenflow doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Zenflow shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Zenflow in its N-PORT filings yet. We sweep new filings monthly.